An Open-labeled Trial of Ramipril in Patients With Migraine
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated.
Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt
to test the efficacy of ramipril on the prophylaxis of migraine attacks.